AAAAAA
Results:
1-21
|
Results: 21
Authors:
Dekeyne, A
Gobert, A
Iob, L
Cistarelli, L
Melon, C
Millan, MJ
Citation: A. Dekeyne et al., Discriminative stimulus properties of the selective norepinephrine reuptake inhibitor, reboxetine, in rats, PSYCHOPHAR, 158(2), 2001, pp. 213-218
Authors:
Dekeyne, A
Iob, L
Millan, MJ
Citation: A. Dekeyne et al., Following long-term training with citalopram, both mirtazapine and mianserin block its discriminative stimulus properties in rats, PSYCHOPHAR, 153(3), 2001, pp. 389-392
Authors:
Millan, MJ
Brocco, M
Gobert, A
Dorey, G
Casara, P
Dekeyne, A
Citation: Mj. Millan et al., Anxiolytic properties of the selective, non-peptidergic CRF1 antagonists, CP154,526 and DMP695: A comparison to other classes of anxiolytic agent, NEUROPSYCH, 25(4), 2001, pp. 585-600
Authors:
Dekeyne, A
Rivet, JM
Gobert, A
Millan, MJ
Citation: A. Dekeyne et al., Generalization of serotonin (5-HT)(1A) agonists and the antipsychotics, clozapine, ziprasidone and S16924, but not haloperidol, to the discriminativestimuli elicited by PD128,907 and 7-OH-DPAT, NEUROPHARM, 40(7), 2001, pp. 899-910
Authors:
Millan, MJ
Dekeyne, A
Papp, M
La Rochelle, CD
Macsweeny, C
Peglion, JL
Brocco, M
Citation: Mj. Millan et al., S33005, a novel ligand at both serotonin and norepinephrine transporters: II. Behavioral profile in comparison with venlafaxine, reboxetine, citalopram, and clomipramine, J PHARM EXP, 298(2), 2001, pp. 581-591
Authors:
Dekeyne, A
Brocco, M
Adhumeau, A
Gobert, A
Millan, MJ
Citation: A. Dekeyne et al., The selective serotonin (5-HT)(1A) receptor ligand, S15535, displays anxiolytic-like effects in the social interaction and Vogel models and suppresses dialysate levels of 5-HT in the dorsal hippocampus of freely-moving rats - A comparison with other anxiolytic agents, PSYCHOPHAR, 152(1), 2000, pp. 55-66
Authors:
Millan, MJ
Gobert, A
Rivet, JM
Adhumeau-Auclair, A
Cussac, D
Newman-Tancredi, A
Dekeyne, A
Nicolas, JP
Lejeune, F
Citation: Mj. Millan et al., Mirtazapine enhances frontocortical dopaminergic and corticolimbic adrenergic, but not serotonergic, transmission by blockade of alpha(2)-adrenergic and serotonin(2C) receptors: a comparison with citalopram, EUR J NEURO, 12(3), 2000, pp. 1079-1095
Authors:
Millan, MJ
Newman-Tancredi, A
Audinot, V
Cussac, D
Lejeune, F
Nicolas, JP
Coge, F
Galizzi, JP
Boutin, JA
Rivet, JM
Dekeyne, A
Gobert, A
Citation: Mj. Millan et al., Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT1B, 5-HT1D and dopamine D-2 and D-3 receptors. Significance for the modulation of frontocortical monoaminergic transmission and depressive states, SYNAPSE, 35(2), 2000, pp. 79-95
Authors:
Gobert, A
Dekeyne, A
Millan, MJ
Citation: A. Gobert et al., The ability of WAY100,635 to potentiate the neurochemical and functional actions of fluoxetine is enhanced by co-administration of SB224,289, but notBRL15572, NEUROPHARM, 39(9), 2000, pp. 1608-1616
Authors:
Dekeyne, A
Denorme, B
Monneyron, S
Millan, MJ
Citation: A. Dekeyne et al., Citalopram reduces social interaction in rats by activation of serotonin (5-HT)(2C) receptors, NEUROPHARM, 39(6), 2000, pp. 1114-1117
Authors:
Millan, MJ
Girardon, S
Monneyron, S
Dekeyne, A
Citation: Mj. Millan et al., Discriminative stimulus properties of the dopamine D-3 receptor agonists, PD128,907 and 7-OH-DPAT: a comparative characterization with novel ligands at D-3 versus D-2 receptors, NEUROPHARM, 39(4), 2000, pp. 586-598
Authors:
Millan, MJ
Dekeyne, A
Newman-Tancredi, A
Cussac, D
Audinot, V
Milligan, G
Duqueyroix, D
Girardon, S
Mullot, J
Boutin, JA
Nicolas, JP
Renouard-Try, A
Lacoste, JM
Cordi, A
Citation: Mj. Millan et al., S18616, a highly potent, spiroimidazoline agonist at alpha(2)-adrenoceptors: I. Receptor profile, antinociceptive and hypothermic actions in comparison with dexmedetomidine and clonidine, J PHARM EXP, 295(3), 2000, pp. 1192-1205
Authors:
Millan, MJ
Lejeune, F
Gobert, A
Brocco, M
Auclair, A
Bosc, C
Rivet, JM
Lacoste, JM
Cordi, A
Dekeyne, A
Citation: Mj. Millan et al., S18616, a highly potent spiroimidazoline agonist at alpha(2)-adrenoceptors: II. Influence on monoaminergic transmission, motor function, and anxiety in comparison with dexmedetomidine and clonidine, J PHARM EXP, 295(3), 2000, pp. 1206-1222
Authors:
Millan, MJ
Dekeyne, A
Rivet, JM
Dubuffet, T
Lavielle, G
Brocco, M
Citation: Mj. Millan et al., S33084, a novel, potent, selective, and competitive antagonist at dopamineD-3-receptors: II. Functional and behavioral profile compared with GR218,231 and L741,626, J PHARM EXP, 293(3), 2000, pp. 1063-1073
Authors:
Millan, MJ
Brocco, M
Rivet, JM
Audinot, V
Newman-Tancredi, A
Maiofiss, L
Queriaux, S
Despaux, N
Peglion, JL
Dekeyne, A
Citation: Mj. Millan et al., S18327 (1-{2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)piperid-1-yl]ethyl}3-phenyl imidazolin-2-one), a novel, potential antipsychotic displaying marked antagonist properties at alpha(1) and alpha(2)-adrenergic receptors: II. Functional profile and a multiparametric comparison with haloperidol, clozapine,and 11 other antipsychotic agents, J PHARM EXP, 292(1), 2000, pp. 54-66
Authors:
Millan, MJ
Girardon, S
Dekeyne, A
Citation: Mj. Millan et al., 5-HT2C receptors are involved in the discriminative stimulus effects of citalopram in rats, PSYCHOPHAR, 142(4), 1999, pp. 432-434
Authors:
Millan, MJ
Gobert, A
Audinot, V
Dekeyne, A
Newman-Tancredi, A
Citation: Mj. Millan et al., Inverse agonists and serotonergic transmission: From recombinant, human serotonin (5-HT)(1B) receptors to G-protein coupling and function in corticolimbic structures in vivo, NEUROPSYCH, 21(2), 1999, pp. S61-S67
Authors:
Dekeyne, A
Girardon, S
Millan, MJ
Citation: A. Dekeyne et al., Discriminative stimulus properties of the novel serotonin (5-HT)(2C) receptor agonist, RO 60-0175: a pharmacological analysis, NEUROPHARM, 38(3), 1999, pp. 415-423
Authors:
Millan, MJ
Schreiber, R
Monneyron, S
Denorme, B
Melon, C
Queriaux, S
Dekeyne, A
Citation: Mj. Millan et al., S-16924, a novel, potential antipsychotic with marked serotonin(1A) agonist properties. IV. A drug discrimination comparison with clozapine, J PHARM EXP, 289(1), 1999, pp. 427-436
Authors:
Millan, MJ
Brocco, M
Gobert, A
Schreiber, R
Dekeyne, A
Citation: Mj. Millan et al., S-16924 [(R)-2-{1-[2-(2,3-dihydro-benzo[1,4]dioxin-5-yloxy)-ethyl]-pyrrolidin-3yl}1-(4-fluorophenyl)-ethanone], a novel, potential antipsychotic withmarked serotonin(1A) agonist properties: III. Anxiolytic actions in comparison with clozapine and haloperidol, J PHARM EXP, 288(3), 1999, pp. 1002-1014
Authors:
Millan, MJ
Gobert, A
Girardon, S
Dekeyne, A
Citation: Mj. Millan et al., Citalopram elicits a discriminative stimulus in rats at a dose selectivelyincreasing extracellular levels of serotonin vs. dopamine and noradrenaline, EUR J PHARM, 364(2-3), 1999, pp. 147-150
Risultati:
1-21
|